Emory University will conduct clinical trial of anthrax vaccine regimen

May 14, 2002

Emory University is one of five sites nationwide selected by the Centers for Disease Control and Prevention (CDC) to conduct a clinical trial of an anthrax vaccination regimen. The study, which is now enrolling volunteers, will use the anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA) in 1970. The new trial is designed to test whether changing the injection method from subcutaneous (under the skin) to the muscle or decreasing the number of doses affects the quality of the immune response or local reactions to the vaccine.

Harry Keyserling, M.D., professor of pediatric infectious diseases at Emory University School of Medicine, is principal investigator for the Emory study. Other sites include Baylor College of Medicine; the Mayo Clinic; the University of Alabama at Birmingham; and Walter Reed Army Medical Center.

Anthrax is a disease caused by the Bacillus anthracis germ, and most often is found in cattle and sheep. Infection with anthrax bacteria may cause skin sores and intestinal or lung illness. Intestinal or lung illness is often serious and may be fatal. Individuals become infected with anthrax when they eat or touch animal parts that contain the bacteria or when they eat, touch or breathe bacteria in the air or on the ground.

The last human clinical trials of the anthrax vaccine were conducted in the 1950s in goat mill workers and in the laboratory scientists who studied anthrax. In 1991, with the threat of Iraqi bioweapons during the Persian Gulf War, the US military began vaccinating soldiers headed to the Persian Gulf. A shortage of vaccine and an exhaustive vaccination schedule that stretched over several years required many soldiers to complete their anthrax immunizations on the battlefield. In 1998, after assessing the threat of biological weapons, the Department of Defense required all U.S. armed forces to receive the anthrax vaccine. More than two million people, mostly in the military, have been immunized since FDA approval of the vaccine in 1970. Currently the vaccine is recommended for those in the military who may be exposed to germ warfare and for scientists who work with anthrax in the laboratory.

The current FDA-approved course for the anthrax vaccine requires an initial dose followed by injections after two weeks, four weeks, six months, twelve months, eighteeen months, and a yearly booster thereafter. These injections are given subcutaneously. Some vaccine recipients have experienced pain and swelling in the arm where the vaccine was given, and investigators believe this local reaction might be avoided if the vaccine is given in the muscle of the arm. In 2000, the U.S. Congress asked the CDC to study the method of injection for the vaccine and the number of doses required.

Participants in the new clinical trial will be randomly placed in one of six study groups to be vaccinated over 43 months. One group will receive the licensed regimen of eight vaccinations under the skin. Another group will receive eight vaccinations of a placebo, which will be saltwater shots. The remaining groups will be vaccinated in the muscle rather than under the skin and will receive fewer vaccine doses. Blood will be drawn following each vaccination to evaluate the protective immune response. No live anthrax bacteria will be used in the study. The vaccine does not contain the whole anthrax germ and cannot cause an anthrax infection.

Nationwide, a total of 1,560 volunteers will be enrolled in the clinical trial. Emory will enroll approximately 200 of these volunteers. Participants must be 18 to 61 years of age and must not have any major health problems. The study will require 25 visits over 43 months. At each visit, participants will either receive a shot, have an investigator look at the shot site, or have blood drawn. Participants will not know which study group they are in until the end of the study. All laboratory tests will be provided free, and participants will receive compensation for each visit.

"The anthrax vaccine has an excellent safety record," says Dr. Keyserling. "We hope this new study will simplify the existing dosing and shot regimen for the vaccine and provide more data to convince an anxious public that the vaccine is safe."
-end-
For additional information about the study, call Dr. Keyserling's research staff at 404-727-4044.

Emory University Health Sciences Center

Related Bacteria Articles from Brightsurf:

Siblings can also differ from one another in bacteria
A research team from the University of Tübingen and the German Center for Infection Research (DZIF) is investigating how pathogens influence the immune response of their host with genetic variation.

How bacteria fertilize soya
Soya and clover have their very own fertiliser factories in their roots, where bacteria manufacture ammonium, which is crucial for plant growth.

Bacteria might help other bacteria to tolerate antibiotics better
A new paper by the Dynamical Systems Biology lab at UPF shows that the response by bacteria to antibiotics may depend on other species of bacteria they live with, in such a way that some bacteria may make others more tolerant to antibiotics.

Two-faced bacteria
The gut microbiome, which is a collection of numerous beneficial bacteria species, is key to our overall well-being and good health.

Microcensus in bacteria
Bacillus subtilis can determine proportions of different groups within a mixed population.

Right beneath the skin we all have the same bacteria
In the dermis skin layer, the same bacteria are found across age and gender.

Bacteria must be 'stressed out' to divide
Bacterial cell division is controlled by both enzymatic activity and mechanical forces, which work together to control its timing and location, a new study from EPFL finds.

How bees live with bacteria
More than 90 percent of all bee species are not organized in colonies, but fight their way through life alone.

The bacteria building your baby
Australian researchers have laid to rest a longstanding controversy: is the womb sterile?

Hopping bacteria
Scientists have long known that key models of bacterial movement in real-world conditions are flawed.

Read More: Bacteria News and Bacteria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.